FLURBIPROFEN

PRODUCT IDENTIFICATION

CAS NO. 5104-49-4 (Racemic Mix)
51543-39-6 (S form)

FLURBIPROFEN

EINECS NO. 225-827-6, 257-263-1
FORMULA C15H13FO2
MOL WT. 244.26

H.S. CODE

 

TOXICITY

 

SYNONYMS 3-Fluoro-4-phenylhydratropic acid;
(±)-2-(2-fluoro-4 biphenylyl) propionic acid; (±)-2-Fluoro-a-methyl-4-biphenylacetic acid;
SMILES

 

CLASSIFICATION

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE white to yellowish crystalline powder
MELTING POINT 114 - 117 C
BOILING POINT

 

SPECIFIC GRAVITY

 

SOLUBILITY IN WATER Slight soluble
pH  
VAPOR DENSITY

 

AUTOIGNITION

 

NFPA RATINGS

Health: 2 Flammability: 0 Reactivity: 0

REFRACTIVE INDEX

 

FLASH POINT

 

STABILITY

Stable under ordinary conditions

GENERAL DESCRIPTION & APPLICATIONS

Flurbiprofen, a derivative of phenylalkanoic acid, a nonsteroidal anti-inflammatory agent; related to ibuprofen in structure; used in the treatment of rheumatoid arthritis and osteoarthritis. It is applied topically to the conjunctiva to inhibit miosis during ophthalmic surgery; administered orally. It is a white to yellowish crystalline powder; slightly soluble in water; soluble in most polar solvents. The chemical designation is (±)-2-(2-fluoro-4 biphenylyl) propionic acid.

Nonsteroidal Antiinflammatory Drugs (NSAIDs); chemically heterogeneous large groups of drugs which suppress inflammation in a manner similar to steroids, but less side effects of sedation, respiratory depression, or addiction than steroids. They are widely used for the treatment of inflammatory disorders and painful conditions such as rheumatoid arthritis, gout, bursitis, painful menstruation, and headache. They are effective in the relief of pain and fever. NSAIDs inhibit the cyclooxygenase (COX) activity resulting in decreased synthesis of prostaglandin, leukotriene and thromboxane precursors such as the ubiquitous enzyme which catalyzes the initial step in the synthesis of prostanoids. Prostanoid is any of a group of C-20 fatty acids complex with an internal five or six carbon rings such as prostaglandins, prostanoic acid, prostacyclins, and thromboxane; derived from arachidonic acid (C-20 polyunsaturated fatty acid with four cis double bonds). The action or the synthesis of prostanoids are involved in the modulation of a variety of pathophysiologic processes including inflammation, hemostasis, thrombosis, cytoprotection,  ulceration, hemodynamics and other the progression of kidney diseases. Thus, NSAIDs as non-selective inhibitors of the cyclooxygenases (both the cyclooxygenase-1 and cyclooxygenase-2 isoenzymes) may have beneficial as well as untoward effects on a variety of human diseases. Low stomach prostanoid levels caused by COX-1 inhibitors can result in ulceration and internal bleeding and perforation. The selective COX-2 inhibitors such as oxicam, meloxicam, and coxibs (celecoxib, rofecoxib, valdecoxib, parecoxib and etoricoxib) do not interfere with COX-1. The most prominent NSAID is aspirin. Nonaspirin NSAIDs can be classified based on chemical structures.

Nonsteroidal Anti-Inflammatory Drugs (NSAID) by chemical structure

  • Carboxylic Acid Groups
    • Salicylates (Acetylsalicylate, Choline salicylate, Diflunisal, Magnesium choline salicylate, Magnesium salicylate, Salsalate)
    • Acetic Acids (Diclofenac sodium, Diclofenac potassium, Etodolac, Indomethacin, Ketorolac, Nabumetone, Sulindac, Tolmetin)
    • Propionic acids (Carprofen, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Loxoprofen, Naproxen, Naproxen sodium, Oxaprozin, Vedaprofen)
    • Anthranilic acids (Meclofenamic acid, Meclofenamate sodium, Tolfenamic acid)
    • Phenylacetic acids
    • Aminonicotinic acids (Flunixin)
    • Indole Analogs (Indomethacin, Nabumetone, Ketorolac, Etodolac,)
  • Enolic Acid Groups (which doesn't have carboxylic group but acid due to the enolic hydroxy substituent)
    • Pyrazolones (Phenylbutazone, Oxyphenbutazone, Dipyrone, Ramifenazone)
    • Oxicams (Meloxicam, Piroxicam, Tenoxicam)
  • Coxibs
    • Celecoxib, Rofecoxib, Valdecoxib, Parecoxib, Etoricoxib
  • Gold Salts
    • Auranofin, Gold sodium thiomalate, Aurothioglucose

SALES SPECIFICATION

BIBLIOGRAPHY

BP

APPEARANCE

White to yellowish crystalline powder

ASSAY

98.5 - 100.5%

HEAVY METALS

10ppm max

MELTING POINT

114 - 117 C

LOSS ON DRYING

0.1% max

TRANSPORTATION
PACKING

 

HAZARD CLASS 6.1 (Packing Group: I)
UN NO. 2811
OTHER INFORMATION
Hazard Symbols: XI, Risk Phrases: 23/24/25-36/37/38, Safety Phrases: 26-36/37/39-45
PRICE

Click to open the table

 

Click to close the table